LOCUS BIOSCIENCES
๐ฎ๐ณIndia
- Country
- ๐ฎ๐ณIndia
- Ownership
- -
- Established
- 1998-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://locuspharma.com
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
Phase 2
Recruiting
- Conditions
- Urinary Tract Infections
- Interventions
- Drug: LBP-EC01 0.1 x IV doseDrug: LBP-EC01 0.01x IV DoseDrug: LBP-EC01 IV Infusion DoseDrug: PlaceboDrug: TMP/SMX
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Locus Biosciences
- Target Recruit Count
- 318
- Registration Number
- NCT05488340
- Locations
- ๐บ๐ธ
Research Site 115, Birmingham, Alabama, United States
๐บ๐ธResearch Site 143, Chula Vista, California, United States
๐บ๐ธResearch Site 138, Fresno, California, United States
Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Locus Biosciences
- Target Recruit Count
- 36
- Registration Number
- NCT04191148
- Locations
- ๐บ๐ธ
Universal Axon - Homestead, LL, Homestead, Florida, United States
๐บ๐ธAMPM Research Clinic, Miami Gardens, Florida, United States
๐บ๐ธInnovation Medical Research Center, Palmetto Bay, Florida, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath